- Home
- XCUR vs BOLD Comparison
XCUR vs BOLD Comparison
Compare XCUR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XCUR | BOLD |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 25.7M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | XCUR | BOLD |
|---|---|---|
| Price | $4.60 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 17.0K | ★ 50.5K |
| Earning Date | 03-13-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $0.96 |
| 52 Week High | $14.11 | $1.78 |
Technical Indicators
Market Signals| Indicator | XCUR | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 50.73 |
| Support Level | $4.48 | $1.15 |
| Resistance Level | $5.13 | $1.19 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 78.54 | 45.83 |
Price Performance
Historical ComparisonAbout XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.